ANGPLT3 interfering RNA therapy reduces triglyceride levels in mixed hyperlipidemia
1. Zodasiran, an RNA interference (RNAi) therapy targeting angiopoietin-like 3 (ANGPTL3), resulted in a dose-dependent reduction in ANGPTL3 and triglyceride ...
Tag: Zodasiran
Zodasiran associated with reduced triglyceride levels among adults with mixed hyperlipidemia
1. In this randomized controlled trial, adults with mixed hyperlipidemia who received zodasiran had dose-dependent decreases in triglyceride levels compared ...